-
New Genialis RNA Biomarker Accurately Predicts KRAS Outcomes in Lung Cancer Patients
09 Apr 2024 20:37 GMT
… KRAS inhibitor currently approved for KRAS G12C non-small cell lung cancers … analyzes foundational aspects of KRAS biology using RNA- … in the KRAS space measure only KRAS mutation status, … available diagnostics to support KRAS-targeted patient care are …
-
Merck begins phase 3 trial of MK-1084, Keytruda combo for first-line treatment of certain patients with Metastatic Non-Small Cell Lung Cancer
06 Apr 2024 05:43 GMT
… non-small cell lung cancer.”
Merck has initiated … of non-small cell lung cancers (adenocarcinoma). Despite … targeting KRAS mutations has been challenging.
Lung cancer is … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer …
-
Cause of rare congenital lung malformations
18 Apr 2024 11:11 GMT
… with an increased risk of lung cancer. Researchers at Hannover Medical School … research team’s hypothesis. The KRAS gene in particular was affected … variants. The children with a KRAS variant had a statistically more …
-
Merck Initiates Phase 3 Clinical Trial of MK-1084 in Combination with KEYTRUDA® for Treatment of Metastatic Non-Small Cell Lung Cancer
04 Apr 2024 17:32 GMT
… an investigational oral selective KRAS G12C inhibitor, in combination … small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C … metastatic non-small cell lung cancer.”
Merck has initiated … previously untreated patients with KRAS G12C-mutated metastatic …
-
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
04 Apr 2024 11:01 GMT
… non-small cell lung cancers (adenocarcinoma). Despite … KRAS mutations has been challenging.
About lung cancer
Lung cancer … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … non-small cell lung cancer (NSCLC), with …
-
TD2 to Present Precision Preclinical Applications for Glioblastoma and Non-Small Cell Lung Cancer at AACR Annual Meeting
03 Apr 2024 12:00 GMT
… targeting non-small cell lung cancer and glioblastoma at the … restoring trametinib sensitivity in lung cancers with a specific mutational … human non-small cell lung cancer cells and tumors following … in KRAS/LKB1 mutant non-small cell lung cancers (Tuesday …
-
BMS shares positive phase 3 results for Krazati in non-small cell lung cancer
03 Apr 2024 11:26 GMT
… metastatic non-small cell lung cancer (NSCLC).
Results from … response rate (ORR).
Lung cancer is estimated to have … locally advanced or metastatic KRAS G12C-mutated lung cancer.
“We are … more patients with KRAS G12C-mutated lung cancer.”
Krazati has already …
-
Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting
09 Apr 2024 20:30 GMT
… cancers, regardless of prior KRAS inhibitor therapy
BOSTON and SOUTH … have plagued single-acting KRAS inhibitors and limited their … rates in patients with lung cancer, compared to a PD … cancer (CRC), non-small cell lung cancer (NSCLC) and pancreatic cancer, …
-
CRISPR-Cas9 Targets Lung Cancer Using Cryo-Shocked Tumor Cells
01 Apr 2024 00:48 GMT
… (LNPs) in treating lung cancer. Rapid liquid nitrogen treatment … of non-small cell lung cancer (NSCLC), this delivery … deliver CRISPR-Cas9 for lung cancer regression by synthetic lethality … cryo-inactivated non-pathogenic KRAS-mutant NSCLC cells were …
-
Phase 3 Trial Launches for Keytruda, MK-1084 in KRAS-Mutant NSCLC
09 Apr 2024 16:37 GMT
… targets the KRAS G12C mutant and inhibits KRAS G12C-mediated … metastatic non-small cell lung cancer.”
Previously untreated patients … Innovation’ in the KRAS-Mutant Lung Cancer Space
In a previous … metastatic non-small cell lung cancer.
Researchers stated that …